Clinical Trial Update: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 clinical trial is evaluating the combination of polatuzumab vedotin with rituximab for post-transplant lymphoproliferative disorder and is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Post-transplant Lymphoproliferative Disorder | Phase 1, Phase 2 | Status: RECRUITING